

## List of Drugs for Rare Cancers in Hong Kong Drug List (by drug categories)

### [Definition of Rare Cancers](#)

Incidence rate of less than 6 per 100,000 persons per year (source: Rare Cancers Europe)

Incidence rate of less than 15 per 100,000 persons per year (source: National Cancer Institute - USA)

### Date Published 20.09.2022

The information in this file is for educational purposes only and is not intended to replace the advice of a physician or other qualified medical professional.

The content of the list is copyrighted by Rare Diseases Hong Kong (RDHK) and may not be reproduced, copied, downloaded or disseminated, in any way, for any commercial purpose, without prior written authorization and approval from RDHK. Individuals may print one hard copy for personal use, provided that content is unmodified and includes RDHK's copyright.

No.	Ingredients	Reference Indication	By BNF Therapeutic Class	Drug Formulary Category*	Source
1	ACTINOMYCIN D	Ewing's sarcoma, Wilm's tumour	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	General Drugs	MIMS HK
2	ASPARAGINASE	Acute lymphoblastic leukaemia	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	General Drugs	MIMS HK
3	BLEOMYCIN	Testicular tumours	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	General Drugs	MIMS HK
4	CARBOPLATIN	Small cell lung cancer	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	General Drugs	MIMS HK
5	CARMUSTINE	Malignant glioma, Recurrent glioblastoma multiforme Hodgkin's disease, Multiple myeloma, Non-Hodgkin's Lymphoma	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	General Drugs	MIMS HK
6	CHLORAMBUCIL	Hodgkin's disease Non-Hodgkin's Lymphoma Waldenstrom's macroglobulinaemia Chronic lymphocytic leukaemia	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	General Drugs	MIMS HK
7	CISPLATIN	Metastatic testicular tumours	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	General Drugs	MIMS HK
8	CYCLOPHOSPHAMIDE	Acute lymphocytic leukaemia, Acute myeloid leukaemia, Advanced mycosis fungoides, Chronic lymphocytic leukaemia, Chronic myeloid leukaemia, Ewing's sarcoma, Hodgkin's Lymphoma, Multiple myeloma, Non-Hodgkin's Lymphoma, Retinoblastoma, Small cell lung cancer	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	General Drugs	MIMS HK
9	CYTARABINE	Leukaemic meningitis	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	General Drugs	MIMS HK
10	DACARBAZINE	Soft tissue sarcoma Metastatic melanoma Hodgkin's disease	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	General Drugs	MIMS HK

11	DAUNORUBICIN	Acute leukaemia AIDS-related Kaposi's sarcoma	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	General Drugs	MIMS HK
12	DOXORUBICIN	Acute leukaemia, Advanced soft tissue sarcoma, Hodgkin's Lymphoma, Osteosarcoma, Wilm's tumour	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	General Drugs	MIMS HK
13	EPIRUBICIN	Acute leukaemia, Multiple myeloma	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	General Drugs	MIMS HK
14	ETOPOSIDE	Small cell lung cancer Testicular cancer	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	General Drugs	MIMS HK
15	FLUOROURACIL	Pancreatic carcinoma Superficial basal cell carcinoma	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	General Drugs	MIMS HK
16	GEMCITABINE	Cancer, pancreatic	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	General Drugs	MIMS HK
17	HYDROXYUREA	chronic myelogenous leukemia	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	General Drugs	MIMS HK
18	IDARUBICIN	Acute myeloid leukaemia Acute lymphoblastic leukaemia	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	General Drugs	MIMS HK
19	IRINOTECAN	Metastatic adenocarcinoma of pancreas	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	General Drugs	MIMS HK
20	LOMUSTINE	Metastatic malignant melanoma, Lung cancer Hodgkin's Lymphoma	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	General Drugs	MIMS HK
21	MELPHALAN	Malignant melanoma, Soft tissue sarcoma Multiple myeloma Polycythemia vera	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	General Drugs	MIMS HK
22	MERCAPTOPYRINE	Acute lymphoblastic leukaemia	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	General Drugs	MIMS HK
23	METHOTREXATE	Acute lymphoblastic leukaemia Choriocarcinoma, Trophoblastic neoplasm Burkitt's Lymphoma	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	General Drugs	MIMS HK

24	MITOMYCIN	Pancreatic, Head and neck cancer Superficial bladder tumours	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	General Drugs	MIMS HK
25	PACLITAXEL	HER2-overexpressing advanced or metastatic breast cancer Metastatic adenocarcinoma of pancreas AIDS-related Kaposi's sarcoma	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	General Drugs	MIMS HK
26	PROCARBAZINE	Hodgkin's disease	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	General Drugs	MIMS HK
27	THIOGUANINE	Acute lymphoblastic leukaemia, Acute myeloid leukaemia, Chronic myeloid leukaemia	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	General Drugs	MIMS HK
28	TRETINOIN	Acute promyelocytic leukaemia	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	General Drugs	MIMS HK
29	VINBLASTINE	Advanced mycosis fungoides, Hodgkin's disease, Kaposi's sarcoma, Langerhans cell histiocytosis, Lymphocytic Lymphoma, Testicular cancer Choriocarcinoma	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	General Drugs	MIMS HK
30	VINCRISTINE	Acute lymphoblastic leukaemia, Acute myeloid leukaemia, Hodgkin's disease, Non-Hodgkin's Lymphoma, Small cell lung cancer, Wilm's tumour	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	General Drugs	MIMS HK
31	THALIDOMIDE	Multiple myeloma	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	General Drugs	MIMS HK
32	OCTREOTIDE	Diarrhoea associated with carcinoid tumour, Flushing associated with carcinoid tumour, Necrolytic migratory erythema associated with glucagonoma, Severe secretory diarrhoea associated with vasoactive intestinal peptide-secreting tumour	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	General Drugs	MIMS HK
33	ARSENIC TRIOXIDE	Acute promyelocytic leukaemia	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Speical Drugs	MIMS HK
34	BLINATUMOMAB	Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukaemia	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Speical Drugs	MIMS HK
35	BUSULPHAN	Chronic myeloid leukemia (CML)	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Speical Drugs	MIMS HK
36	CETUXIMAB	Locally advanced squamous cell carcinoma of the head and neck Metastatic squamous cell carcinoma of the head and neck, Recurrent squamous cell carcinoma of the head and neck	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Speical Drugs	MIMS HK

37	CLADRIBINE	B cell chronic lymphocytic leukaemia Hairy cell leukaemia Waldenstrom's macroglobulinaemia	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Spceial Drugs	MIMS HK
38	CLOFARABINE	Acute lymphoblastic leukaemia	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Spceial Drugs	MIMS HK
39	CRISANTASPASE (ASPARAGINASE ERW)	Acute lymphoblastic leukaemia	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Spceial Drugs	MIMS HK
40	DASATINIB	Chronic myeloid leukaemia	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Spceial Drugs	MIMS HK
41	DOCETAXEL	Head and neck cancer	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Spceial Drugs	MIMS HK
42	ERLOTINIB	Metastatic pancreatic cancer	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Spceial Drugs	MIMS HK
43	EVEROLIMUS (AFINITOR) (OR EQUIV)	Neuroendocrine tumours of pancreatic origin Neuroendocrine tumours of gastrointestinal origin, Neuroendocrine tumours of lung origin	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Spceial Drugs	MIMS HK
44	FLUDARABINE	B cell chronic lymphocytic leukaemia	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Spceial Drugs	MIMS HK
45	IFOSFAMIDE	Germ cell testicular carcinoma	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Spceial Drugs	MIMS HK
46	IMATINIB	Accelerated phase Philadelphia chromosome positive chronic myelogenous leukaemia, Blast phase Philadelphia chromosome positive chronic myelogenous leukaemia Chronic phase Philadelphia chromosome positive chronic myelogenous leukaemia Philadelphia chromosome-positive acute lymphoblastic leukaemia Myelodysplastic/myeloproliferative disease Gastrointestinal stromal tumour Dermatofibrosarcoma protuberans	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Spceial Drugs	MIMS HK
47	MITOXANTRONE	Blast crisis in chronic myeloid leukaemia Non-Hodgkin's Lymphoma Acute myeloid leukaemia	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Spceial Drugs	MIMS HK
48	PEGASPARAGINASE	Acute lymphoblastic leukaemia	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Spceial Drugs	MIMS HK

49	PEMETREXED	Malignant pleural mesothelioma	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Speical Drugs	MIMS HK
50	TEMOZOLOMIDE	Glioblastoma multiforme Refractory anaplastic astrocytoma Anaplastic astrocytoma, Recurrent glioblastoma multiforme	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Speical Drugs	MIMS HK
51	ALEMTUZUMAB (LEMTRADA)	B cell chronic lymphocytic leukaemia	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Speical Drugs	MIMS HK
52	RITUXIMAB	Refractory follicular Lymphoma, Relapsed follicular Lymphoma CD20-positive diffuse large B cell non-Hodgkin's Lymphoma Chronic lymphocytic leukaemia Advanced follicular non-Hodgkin's Lymphoma CD20-positive non-progressing low-grade non-Hodgkin's Lymphoma	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Speical Drugs	MIMS HK
53	LANREOTIDE	Carcinoid syndrome	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Speical Drugs	MIMS HK
54	ACALABRUTINIB	Relapsed / refractory chronic lymphocytic leukaemia (CLL) 復發或難治慢性淋巴細胞白血病	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item With Safety Net (Samaritan Fund)	HA Website
55	ALECTINIB	ALK+ve non-small cell lung cancer (NSCLC) (first-line treatment) 間變性淋巴瘤激酶(ALK)呈陽性非小細胞肺癌 (一線治療) ALK+ve metastatic non-small cell lung cancer (NSCLC), progressed on Crizotinib and intolerant to Ceritinib, or have CNS-progression after Crizotinib ALK 陽性的晚期非小細胞肺癌 · 患者接受克唑替尼治療中惡化而對塞瑞替尼不耐受 · 或曾接受過克唑替尼治療而出現中樞神經系統轉移	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item With Safety Net (Samaritan Fund)	HA Website
56	AZACITIDINE	Acute myeloid leukaemia (AML) 急性骨髓性白血病 Chronic myelomonocytic leukaemia (CMML) 慢性粒單細胞白血病 Myelodysplastic syndromes (MDS) 骨髓增生異常綜合症	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item With Safety Net (Samaritan Fund)	HA Website
57	Axitinib	Advanced renal cell carcinoma (RCC)	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item With Safety Net (CCF Medical Assistance)	HA Website

58	BENDAMUSTINE	Chronic lymphocytic leukaemia Multiple myeloma Non-Hodgkin's Lymphoma	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item With Safety Net (Samaritan Fund)	MIMS HK
59	BEVACIZUMAB	With carboplatin and paclitaxel for front-line fallopian tube / primary peritoneal cancer 與卡铂和紫杉醇併用於晚期輸卵管癌和原發性腹膜癌的第一線治療	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item With Safety Net (CCF Medical Assistance)	HA Website
60	BORTEZOMIB	Multiple myeloma Mantle cell Lymphoma	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item With Safety Net (Samaritan Fund)	MIMS HK
61	BRENTUXIMAB VEDOTIN	For the treatment of adult patients with relapsed or refractory CD30+ Hodgkin Lymphoma (RR/HL): (i) following autologous stem cell transplant (ASCT), or (ii) following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option 用於成人患者，治療復發或難治性 CD30+型何傑金氏淋巴瘤(HL)，而患者： (i) 已接受自身幹細胞移植，或 (ii) 經歷最少兩類自身幹細胞移植或多項化療的療程均屬不合適的選項  For the treatment of adult patients with relapsed or refractory systemic anaplastic large cell Lymphoma 用於成人患者，治療復發或難治性全身間變性大型細胞淋巴瘤  For the treatment of adult patients with CD30+ cutaneous T-cell Lymphoma (CTCL) after at least 1 prior systemic therapy 用於成人患者，治療 CD30+皮膚型 T 細胞淋巴瘤，且先前至少已接受一種全身性治療	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
62	CARFILZOMIB	Multiple myeloma	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item With Safety Net (Samaritan Fund)	MIMS HK
63	CERITINIB	ALK+ve non-small cell lung cancer (NSCLC) ALK 呈陽性非小細胞肺癌  For adult patients with ALK+ve advanced non-small cell lung cancer (NSCLC) previously treated with Crizotinib 曾經接受克唑替尼療程，ALK 呈陽性晚期非小細胞肺癌的成年患者	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item With Safety Net (Samaritan Fund & CCF Medical Assistance Programmes)	HA Website
64	CRIZOTINIB	ALK+ve non-small cell lung cancer (NSCLC) ALK 呈陽性非小細胞肺癌  ROS1-positive non-small cell lung cancer (NSCLC) ROS1 呈陽性非小細胞肺癌	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item With Safety Net (Samaritan Fund)	HA Website

65	DABRAFENIB	For the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma 用於成年患者以治療BRAF V600突變呈陽性而不能切除的或轉移性黑色素瘤  For the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection 作為術後輔助治療，用於已完全切除腫瘤的BRAF V600突變III期黑色素瘤成人患者	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
66	DASATINIB	Imatinib-resistant chronic myeloid leukaemia (CML) 對伊馬替尼(Imatinib)具抗藥性的慢性骨髓性白血病  Imatinib-resistant philadelphia or BCR/ABL positive acute lymphoblastic leukaemia (ALL) 對伊馬替尼(Imatinib)具抗藥性及伴有費城染色體的急性淋巴細胞白血病  Newly diagnosed chronic myeloid leukaemia (CML) in chronic phase 處於慢性期及新斷症的慢性骨髓性白血病  Nilotinib-resistant chronic myeloid leukaemia (CML) 對尼洛替尼(Nilotinib)具抗藥性的慢性骨髓性白血病	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item With Safety Net (Samaritan Fund)	HA Website
67	Gemtuzumab Ozogamicin	In combination with daunorubicin and cytarabine for the treatment of patients age 15 years and above with previously untreated, de novo CD33-positive acute myeloid leukaemia (AML), except acute promyelocytic leukaemia (APL) 與柔紅霉素及阿糖胞苷結合使用，用作治療15歲及以上患有原發性CD33型呈陽性的急性骨髓性白血病(急性早幼骨髓性白血病除外)，而之前未曾接受治療的患者	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
68	IBRUTINIB	Relapsed or refractory mantle cell Lymphoma (MCL) 復發或難治性套細胞淋巴瘤  Chronic lymphocytic leukaemia (CLL) 慢性淋巴細胞白血病	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item With Safety Net (Samaritan Fund)	HA Website
69	IMATINIB	Gastrointestinal stromal tumour 胃腸道間質瘤	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item With Safety Net (Samaritan Fund)	HA Website
70	INOTUZUMAB OZOGAMICIN	As monotherapy for the treatment of transplant-eligible adult patients with relapsed or refractory CD22-positive B cell acute lymphoblastic leukaemia (ALL) that is either Philadelphia chromosome negative, or Philadelphia chromosome positive failing at least 1 prior TKI treatment 作為單一使用的藥物，用於治療適合移植的復發或難治性CD22陽性B細胞急性淋巴細胞白血病的成年患者，並為費城染色體陰性或費城染色體陽性而之前使用過至少一種酪氨酸激酶抑制劑(TKI)治療無效	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
71	IXAZOMIB	In combination with dexamethasone for the treatment of multiple myeloma in patients who have received at least one prior therapy 與地塞米松組合使用，用於治療曾接受最少一次先前療程的多發性骨髓瘤患者	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item With Safety Net (CCF Medical Assistance)	HA Website
72	LENVATINIB	For first-line treatment of patients with unresectable hepatocellular carcinoma (HCC) 用於無法以手術切除腫瘤的肝癌病人，作第一線治療	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item With Safety Net (CCF Medical Assistance)	HA Website

73	MIDOSTAURIN	Acute myeloid leukaemia (AML) 急性骨髓性白血病	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item With Safety Net (Samaritan Fund)	HA Website
74	NILOTINIB	Dasatinib-resistant chronic myeloid leukaemia (CML) 對達沙替尼(Dasatinib) 具抗藥性的慢性骨髓性白血病  Imatinib-resistant chronic myeloid leukaemia (CML) 對伊馬替尼(Imatinib) 具抗藥性的慢性骨髓性白血病  Newly diagnosed chronic myeloid leukaemia (CML) in chronic phase 處於慢性期及新斷症的慢性骨髓性白血病	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item With Safety Net (Samaritan Fund)	HA Website
75	NIVOLUMAB	As monotherapy for BRAF V600 wild-type unresectable or metastatic melanoma 適用於治療 BRAF V600 野生型不可切除或轉移性黑色素瘤之單一藥劑治療  For adjuvant treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection 作為輔助性治療，用於腫瘤已擴散至淋巴結或其他部位，並已完全切除腫瘤的黑色素瘤患者  For the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after platinum based therapy 治療接受含鉑化學治療時或之後疾病惡化的復發或轉移性頭頸部鱗狀細胞癌(SCCHN)病人	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
76	OBINUTUZUMAB	Follicular Lymphoma 濾泡性淋巴瘤  In combination with Chlorambucil for treatment of previously untreated chronic lymphocytic leukaemia (CLL) in adult patients with comorbidities making them unsuitable for full-dose Fludarabine or Bendamustine based therapy 適用於與苯丁酸氮芥(Chlorambucil)併用，治療先前未曾接受過治療，且具有合併症而不適合接受全劑量含氟達拉濱(Fludarabine)或苯達莫司汀(Bendamustine)治療的慢性淋巴細胞白血病患者	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item With Safety Net (Samaritan Fund & CCF Medical Assistance Programmes)	HA Website
77	OLAPARIB	As maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response after first-line platinumbased chemotherapy (FIGO III-IV 期) 高分化晚期上皮性卵巢癌，輸卵管癌或原發性腹膜癌成人患者，有 BRCA 1/2 基因突變 (生殖細胞及 / 或體細胞突變) 而完成一線鉑類化療療程後有完全或部分緩解的維持治療	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website



78	PEMBROLIZUMAB	<p>For first-line treatment for metastatic non-small cell lung cancer (NSCLC) with high PD-L1 expression (Tumor Proportion Score <math>\geq</math> 50%) with no EGFR or ALK genomic tumor aberrations 用於PD-L1水平高 (腫瘤比例評分 <math>\geq</math>50%) · 且沒有表皮生長因子受體(EGFR)或間變性淋巴瘤激酶(ALK)基因突變的轉移性非小細胞肺癌的成年患者 · 作一線治療</p> <p>Treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy 治療局部晚期或轉移性泌尿道上皮癌 · 用於在接受鉑類組合化療期間或之後出現病情惡化 · 或於十二個月內接受過鉑類組合化療作為術前或術後治療的患者</p> <p>As monotherapy for the treatment of adult patients with relapsed or refractory classical Hodgkin Lymphoma (cHL) who have failed autologous stem cell transplant (ASCT) and Brentuximab Vedotin (BV), or who are transplant-ineligible and have failed BV 單一治療用於成人患者 · 治療復發或難治性典型何傑金氏淋巴瘤(cHL) · 而患者已曾接受自身幹細胞移植(ASCT)及維布妥昔單抗(BV)治療但失敗 · 或不合適自身幹細胞移植及曾接受維布妥昔單抗(BV)治療但失敗</p>	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
79	PONATINIB	<p>Acute lymphoblastic leukaemia (ALL) 急性淋巴細胞白血病</p> <p>Chronic myeloid leukaemia (CML) 慢性骨髓性白血病</p>	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item With Safety Net (Samaritan Fund)	HA Website
80	RUXOLITINIB	<p>Post-essential thrombocythaemia myelofibrosis, Post-polycythaemia vera myelofibrosis, Primary myelofibrosis</p> <p>Polycythemia vera</p>	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item With Safety Net (Samaritan Fund)	MIMS HK
81	SORAFENIB	<p>Hepatocellular carcinoma (HCC) 肝細胞癌</p>	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item With Safety Net (Samaritan Fund)	HA Website
82	TEMOZOLOMIDE	<p>Recurrent high grade glioma 復發的惡性神經膠質瘤</p>	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item With Safety Net (Samaritan Fund)	HA Website
83	TRAMETINIB	<p>For the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma 用於成年患者以治療BRAF V600突變呈陽性而不能切除的或轉移性黑色素瘤</p> <p>For the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection 作為術後輔助治療 · 用於已完全切除腫瘤的 BRAF V600突變 III 期黑色素瘤成人患者</p>	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
84	VEMURAFENIB	<p>As monotherapy for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma 用於成年病人以治療 BRAF V600 突變呈陽性而不能切除的或轉移性黑色素瘤的單一療法</p>	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item With Safety Net (CCF Medical Assistance)	HA Website

85	CLADRIBINE (MAVENCLAD)	B cell chronic lymphocytic leukaemia  Hairy cell leukaemia  Waldenstrom's macroglobulinaemia	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item With Safety Net (Samaritan Fund)	MIMS HK
86	INTERFERON GAMMA	Chronic granulomatous disease, Malignant osteopetrosis	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item With Safety Net (Samaritan Fund)	MIMS HK
87	LENALIDOMIDE	Multiple myeloma (MM) 多發性骨髓瘤  In combination with dexamethasone for the treatment of multiple myeloma in patients who have received at least one prior therapy 與地塞米松組合使用·用於治療曾接受最少一次先前療程的多發性骨髓瘤患者	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item With Safety Net (Samaritan Fund & CCF Medical Assistance Programmes)	HA Website
88	POMALIDOMIDE	Multiple myeloma (MM) 多發性骨髓瘤	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item With Safety Net (Samaritan Fund)	HA Website
89	RITUXIMAB	Maintenance therapy for relapsed follicular Lymphoma (RFL) 復發濾泡性淋巴瘤的維持性治療  Previously-untreated and relapsed / refractory chronic lymphocytic leukaemia (CLL) 從未治療及復發 / 難治慢性淋巴細胞白血病  CD20 positive diffuse large B-cell Lymphoma, Burkitt Lymphoma / Burkitt leukaemia 瀰漫性大型 B 細胞非何杰金氏淋巴瘤、伯基特淋巴瘤 / 伯基特白血病	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item With Safety Net (Samaritan Fund)	HA Website
90	ABIRATERONE	For metastatic castration resistant prostate cancer (mCRPC) progressed on or after docetaxel-based chemotherapy regimen 適用於治療藥物或手術去勢抗性的轉移性前列腺癌·並且已使用過多西紫杉醇(Docetaxel)而治療無效者  For the treatment of adult men with metastatic castration resistant prostate cancer (mCRPC) who are unsuitable for Docetaxel treatment on the basis of predicted intolerance to Docetaxel 適用於治療成年男性藥物或手術去勢抗性的轉移性前列腺癌·而基於預期對多西紫杉醇(Docetaxel)治療不耐受·患者不適合接受多西紫杉醇(Docetaxel)治療	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
91	ENZALUTAMIDE	For metastatic castration resistant prostate cancer (mCRPC) progressed on or after docetaxel-based chemotherapy regimen 適用於治療藥物或手術去勢抗性的轉移性前列腺癌·並且已使用過多西紫杉醇(Docetaxel)而治療無效者  For the treatment of adult men with metastatic castration resistant prostate cancer (mCRPC) who are unsuitable for Docetaxel treatment on the basis of predicted intolerance to Docetaxel 適用於治療成年男性藥物或手術去勢抗性的轉移性前列腺癌·而基於預期對多西紫杉醇(Docetaxel)治療不耐受·患者不適合接受多西紫杉醇(Docetaxel)治療	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website

92	Plerixafor	Multiple myeloma (MM) 多發性骨髓瘤  Non-Hodgkin's Lymphoma (NHL) 非何傑金氏淋巴瘤	NUTRITION AND BLOOD	Self-financed item With Safety Net (Samaritan Fund)	HA Website
93	ACALABRUTINIB	Mantle cell Lymphoma (MCL) in adult patients who have received at least 1 prior therapy. Chronic lymphocytic leukemia (CLL) in adults.	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item Without Safety Net	MIMS HK
94	ATEZOLIZUMAB	Locally advanced urothelial carcinoma, Metastatic urothelial carcinoma	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item Without Safety Net	MIMS HK
95	BENDAMUSTINE	Chronic lymphocytic leukaemia  Multiple myeloma  Non-Hodgkin's Lymphoma	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item Without Safety Net	MIMS HK
96	BEVACIZUMAB	Cervical cancer  Glioblastoma	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item Without Safety Net	MIMS HK
97	BORTEZOMIB	Multiple myeloma  Mantle cell Lymphoma	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item Without Safety Net	MIMS HK
98	BRENTUXIMAB VEDOTIN	Hodgkin's disease  Anaplastic large cell Lymphoma  CD-30 positive cutaneous T-cell Lymphoma	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item Without Safety Net	MIMS HK
99	CABOZANTINIB (CABOMETYX)	Monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults who have previously been treated w/ sorafenib.	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item Without Safety Net	MIMS HK
100	CARFILZOMIB	Multiple myeloma	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item Without Safety Net	MIMS HK
101	CETUXIMAB	Locally advanced squamous cell carcinoma of the head and neck  Metastatic squamous cell carcinoma of the head and neck, Recurrent squamous cell carcinoma of the head and neck	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item Without Safety Net	MIMS HK
102	DARATUMUMAB	Multiple myeloma	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item Without Safety Net	MIMS HK
103	DOCETAXEL	Head and neck cancer	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item Without Safety Net	MIMS HK

104	DOXORUBICIN (LIPOSOMAL)	Acute leukaemia, Advanced soft tissue sarcoma, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Osteosarcoma, Wilm's tumour  AIDS-related Kaposi's sarcoma  Multiple myeloma	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item Without Safety Net	MIMS HK
105	EVEROLIMUS (AFINITOR) (OR EQUIV)	Unresectable or metastatic, well- or moderately-differentiated neuroendocrine tumours of pancreatic origin in adults w/ progressive disease.	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item Without Safety Net	MIMS HK
106	LENVATINIB	Unresectable hepatocellular carcinoma	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item Without Safety Net	MIMS HK
107	NIRAPARIB (TOSYLATE)	Fallopian tube, primary peritoneal cancer	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item Without Safety Net	MIMS HK
108	NIVOLUMAB	Locally advanced squamous cell carcinoma of the head and neck, Metastatic squamous cell carcinoma of the head and neck, Metastatic urothelial carcinoma, Refractory classical Hodgkin Lymphoma, Relapsed classical Hodgkin Lymphoma  Hepatocellular carcinoma  Metastatic melanoma	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item Without Safety Net	MIMS HK
109	OBINUTUZUMAB	Follicular Lymphoma  Chronic lymphocytic leukaemia  Refractory follicular Lymphoma, Relapsed follicular Lymphoma	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item Without Safety Net	MIMS HK
110	PACLITAXEL (ALBUMIN)	HER2-overexpressing advanced or metastatic breast cancer  Metastatic adenocarcinoma of pancreas  AIDS-related Kaposi's sarcoma	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item Without Safety Net	MIMS HK
111	PAZOPANIB	Advanced soft tissue sarcoma	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item Without Safety Net	MIMS HK

112	PEMBROLIZUMAB	<p>PD-L1 expression in metastatic gastroesophageal junction adenocarcinoma, PD-L1 expression in recurrent locally advanced gastroesophageal junction adenocarcinoma</p> <p>PD-L1 expression in metastatic cervical cancer, PD-L1 expression in recurrent cervical cancer</p> <p>PD-L1 expression in metastatic squamous cell carcinoma of the head and neck, PD-L1 expression in unresectable recurrent squamous cell carcinoma of the head and neck</p> <p>Metastatic melanoma</p> <p>Metastatic squamous cell carcinoma of the head and neck, Recurrent squamous cell carcinoma of the head and neck</p> <p>Refractory classical Hodgkin Lymphoma, Relapsed classical Hodgkin Lymphoma</p> <p>Primary mediastinal large B-cell Lymphoma</p> <p>Metastatic urothelial carcinoma</p> <p>Metastatic microsatellite instability-high colorectal cancer</p>	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item Without Safety Net	MIMS HK
113	POLATUZUMAB VEDOTIN	Refractory diffuse large B-cell Lymphoma, Relapsed diffuse large B-cell Lymphoma	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item Without Safety Net	MIMS HK
114	REGORAFENIB	Unresectable, metastatic malignant gastrointestinal stromal tumours	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item Without Safety Net	MIMS HK
115	SUNITINIB	<p>Advanced Renal Cell Carcinoma (RCC)</p> <p>Advanced Pancreatic Neuroendocrine Tumors (pNET)</p>	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item Without Safety Net	MIMS HK
116	TOPOTECAN	<p>Small cell lung cancer</p> <p>Cervical cancer</p> <p>Small cell lung cancer</p>	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item Without Safety Net	MIMS HK
117	VENETOCLAX	<p>Chronic lymphocytic leukaemia, Small lymphocytic Lymphoma</p> <p>Acute myeloid leukaemia</p>	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item Without Safety Net	MIMS HK
118	LENALIDOMIDE	<p>Multiple myeloma</p> <p>Myelodysplastic syndrome</p> <p>Mantle cell Lymphoma</p> <p>Follicular Lymphoma, Marginal zone Lymphoma</p>	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item Without Safety Net	MIMS HK

119	RITUXIMAB	Refractory follicular Lymphoma, Relapsed follicular Lymphoma CD20-positive diffuse large B cell non-Hodgkin's Lymphoma Chronic lymphocytic leukaemia Advanced follicular non-Hodgkin's Lymphoma CD20-positive non-progressing low-grade non-Hodgkin's Lymphoma	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item Without Safety Net	MIMS HK
120	LORLATINIB	Metastatic non-small cell lung carcinoma	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	Self-financed item Without Safety Net	MIMS HK

**Hospital Authority "Drug Formulary" categories\***

General Drugs

These are drugs with well-established indications and cost-effectiveness which are available for general use as indicated by patients with relevant clinical conditions and provided at standard fees and charges in public hospitals and clinics.

Special Drugs

These are drugs used under specific clinical conditions with specific specialist authorisation. Special drugs are provided at standard fees and charges in public hospitals and clinics when prescribed under specific clinical conditions. Patients who do not meet the specified clinical conditions but choose to use Special drugs are required to pay for the drugs.

Self-financed Items (SFIs) with Safety Net

These are drugs which are proven to be of significant clinical benefits but are very expensive for HA to provide as part of its standard services. These drugs are not covered by the standard fees and charges in public hospitals and clinics. Patients who require these drugs and can afford the costs have to purchase the drugs at their own expense. A safety net is provided through relevant funds to subsidize the drug expenses of patients who have financial difficulties.

SFIs without Safety Net

These include drugs with preliminary medical evidence only, drugs with marginal benefits over available alternatives but at significant higher costs, and lifestyle drugs (e.g. anti-obesity drugs). These drugs are not provided as part of HA's standard services nor covered by the standard fees and charges in public hospitals and clinics. Patients who choose to use these drugs must purchase them at their own expense.

\*Reference: HA Drug Formulary Website

## List of Drugs for Rare Cancers in Hong Kong (by cancer types)

### Definition of Rare Cancers

Incidence rate of less than 6 per 100,000 persons per year (source: Rare Cancers Europe)

Incidence rate of less than 15 per 100,000 persons per year (source: National Cancer Institute - USA)

### Date Published 20.09.2022

The information in this file is for educational purposes only and is not intended to replace the advice of a physician or other qualified medical professional.

The content of the list is copyrighted by Rare Diseases Hong Kong (RDHK) and may not be reproduced, copied, downloaded or disseminated, in any way, for any commercial purpose, without prior written authorization and approval from RDHK. Individuals may print one hard copy for personal use, provided that content is unmodified and includes RDHK's copyright.

No.	Ingredients	Indications	Cancer Types	Drug Categories*	Sources of drug information
1	MITOMYCIN	Superficial bladder tumours	Bladder cancer	General Drugs	MIMS HK
2	ATEZOLIZUMAB	Locally advanced urothelial carcinoma	Bladder cancer	Self-financed item Without Safety Net	MIMS HK
3	ATEZOLIZUMAB	Metastatic urothelial carcinoma	Bladder cancer	Self-financed item Without Safety Net	MIMS HK
4	NIVOLUMAB	Metastatic urothelial carcinoma	Bladder cancer	Self-financed item Without Safety Net	MIMS HK
5	PEMBROLIZUMAB	Metastatic urothelial carcinoma	Bladder cancer	Self-financed item Without Safety Net	MIMS HK
6	BRENTUXIMAB VEDOTIN	For the treatment of adult patients with relapsed or refractory CD30+ Hodgkin Lymphoma (RR/HL): (i) following autologous stem cell transplant (ASCT), or (ii) following at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option 用於成人患者 · 治療復發或難治性 CD30+型何傑金氏淋巴瘤(HL) · 而患者： (i) 已接受自身幹細胞移植 · 或	Blood and bone marrow cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
7	BRENTUXIMAB VEDOTIN	For the treatment of adult patients with relapsed or refractory systemic anaplastic large cell Lymphoma 用於成人患者 · 治療復發或難治性全身間變性大型細胞淋巴瘤	Blood and bone marrow cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
8	BRENTUXIMAB VEDOTIN	For the treatment of adult patients with CD30+ cutaneous T-cell Lymphoma (CTCL) after at least 1 prior systemic therapy 用於成人患者 · 治療 CD30+皮膚型 T 細胞淋巴瘤 · 且先前至少已接受一種全身性治療	Blood and bone marrow cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
9	Gemtuzumab Ozogamicin	In combination with daunorubicin and cytarabine for the treatment of patients age 15 years and above with previously untreated, de novo CD33-positive Acute myeloid leukaemia (AML), except Acute promyelocytic leukaemia (APL) 與柔紅霉素及阿糖胞苷結合使用 · 用作治療 15 歲及以上患有原發性 CD33 型呈陽性的急性骨髓性白血病 (急性早幼骨髓性白血病除外) · 而之前未曾接受治療的患者	Blood and bone marrow cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
10	INOTUZUMAB OZOGAMICIN	As monotherapy for the treatment of transplant-eligible adult patients with relapsed or refractory CD22-positive B cell Acute lymphoblastic leukaemia (ALL) that is either Philadelphia chromosome negative, or Philadelphia chromosome positive failing at least 1 prior TKI treatment 作為單一使用的藥物 · 用於治療適合移植的復發或難治性 CD22 陽性 B 細胞急性淋巴細胞白血病的成年患者 · 並為費城染色體陰性或費城染色體陽性而之前使用過至少一種酪氨酸激酶抑制劑(TKI)治療無效	Blood and bone marrow cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
11	ACALABRUTINIB	Relapsed / refractory Chronic lymphocytic leukaemia (CLL) 復發或難治慢性淋巴細胞白血病	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
12	AZACITIDINE	Acute myeloid leukaemia (AML) 急性骨髓性白血病	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
13	AZACITIDINE	Chronic myelomonocytic leukaemia (CMML) 慢性粒單細胞白血病	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
14	AZACITIDINE	Myelodysplastic syndromes (MDS) 骨髓增生異常綜合症	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
15	BENDAMUSTINE	Chronic lymphocytic leukaemia	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	MIMS HK
16	BORTEZOMIB	Mantle cell Lymphoma	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	MIMS HK
17	DASATINIB	Imatinib-resistant Chronic myeloid leukaemia (CML) 對伊馬替尼(Imatinib)具抗藥性的慢性骨髓性白血病	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website

18	DASATINIB	Imatinib-resistant philadelphia or BCR/ABL positive Acute lymphoblastic leukaemia (ALL) 對伊馬替尼(Imatinib)具抗藥性及伴有費城染色體的急性淋巴細胞白血病	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
19	DASATINIB	Newly diagnosed Chronic myeloid leukaemia (CML) in chronic phase 處於慢性期及新斷症的慢性骨髓性白血病	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
20	DASATINIB	Nilotinib-resistant Chronic myeloid leukaemia (CML) 對尼洛替尼(Nilotinib)具抗藥性的慢性骨髓性白血病	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
21	IBRUTINIB	Relapsed or refractory mantle cell Lymphoma (MCL) 復發或難治性套細胞淋巴瘤	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
22	IBRUTINIB	Chronic lymphocytic leukaemia (CLL) 慢性淋巴細胞白血病	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
23	MIDOSTAURIN	Acute myeloid leukaemia (AML) 急性骨髓性白血病	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
24	NILOTINIB	Dasatinib-resistant Chronic myeloid leukaemia (CML) 對達沙替尼(Dasatinib)具抗藥性的慢性骨髓性白血病	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
25	NILOTINIB	Imatinib-resistant Chronic myeloid leukaemia (CML) 對伊馬替尼(Imatinib)具抗藥性的慢性骨髓性白血病	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
26	NILOTINIB	Newly diagnosed Chronic myeloid leukaemia (CML) in chronic phase 處於慢性期及新斷症的慢性骨髓性白血病	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
27	PONATINIB	Acute lymphoblastic leukaemia (ALL) 急性淋巴細胞白血病	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
28	PONATINIB	Chronic myeloid leukaemia (CML) 慢性骨髓性白血病	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
29	RUXOLITINIB	Post-essential thrombocythaemia myelofibrosis	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	MIMS HK
30	RUXOLITINIB	Post-polycythaemia vera myelofibrosis	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	MIMS HK
31	RUXOLITINIB	Primary myelofibrosis	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	MIMS HK
32	RUXOLITINIB	Polycythemia vera	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	MIMS HK
33	CLADRIBINE (MAVENCLAD)	B cell Chronic lymphocytic leukaemia	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	MIMS HK
34	CLADRIBINE (MAVENCLAD)	Hairy cell leukaemia	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	MIMS HK
35	RITUXIMAB	Maintenance therapy for relapsed follicular Lymphoma (RFL) 復發濾泡性淋巴瘤的維持性治療	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
36	RITUXIMAB	Previously-untreated and relapsed / refractory Chronic lymphocytic leukaemia (CLL) 從未治療及復發 / 難治慢性淋巴細胞白血病	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
37	RITUXIMAB	CD20 positive diffuse large B-cell Lymphoma 瀰漫性大型 B 細胞非何杰金氏淋巴瘤	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
38	RITUXIMAB	CD20 positive diffuse Burkitt Lymphoma 瀰漫性伯基特淋巴瘤	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
39	RITUXIMAB	CD20 positive diffuse Burkitt leukaemia 瀰漫性伯基特白血病	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
40	OBINUTUZUMAB	In combination with Chlorambucil for treatment of previously untreated Chronic lymphocytic leukaemia (CLL) in adult patients with comorbidities making them unsuitable for full-dose Fludarabine or Bendamustine based therapy 適用於與苯丁酸氮芥(Chlorambucil)併用，治療先前未曾接受過治療，且具有合併症而不適合接受全劑量氟達拉濱(Fludarabine)或苯達莫司汀(Bendamustine)治療的慢性淋巴細胞白血病患者	Blood and bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund & CCF Medical Assistance Programmes)	HA Website
41	ASPARAGINASE	Acute lymphoblastic leukaemia	Blood and bone marrow cancer	General Drugs	MIMS HK
42	CHLORAMBUCIL	Chronic lymphocytic leukaemia	Blood and bone marrow cancer	General Drugs	MIMS HK
43	CYCLOPHOSPHAMIDE	Acute lymphocytic leukaemia	Blood and bone marrow cancer	General Drugs	MIMS HK



44	CYCLOPHOSPHAMIDE	Acute myeloid leukaemia	Blood and bone marrow cancer	General Drugs	MIMS HK
45	CYCLOPHOSPHAMIDE	Chronic lymphocytic leukaemia	Blood and bone marrow cancer	General Drugs	MIMS HK
46	CYCLOPHOSPHAMIDE	Chronic myeloid leukaemia	Blood and bone marrow cancer	General Drugs	MIMS HK
47	CYTARABINE	Leukaemic meningitis	Blood and bone marrow cancer	General Drugs	MIMS HK
48	DAUNORUBICIN	Acute leukaemia	Blood and bone marrow cancer	General Drugs	MIMS HK
49	DOXORUBICIN	Acute leukaemia	Blood and bone marrow cancer	General Drugs	MIMS HK
50	EPIRUBICIN	Acute leukaemia	Blood and bone marrow cancer	General Drugs	MIMS HK
51	HYDROXYUREA	chronic myelogenous leukaemia	Blood and bone marrow cancer	General Drugs	MIMS HK
52	IDARUBICIN	Acute myeloid leukaemia	Blood and bone marrow cancer	General Drugs	MIMS HK
53	IDARUBICIN	Acute lymphoblastic leukaemia	Blood and bone marrow cancer	General Drugs	MIMS HK
54	MELPHALAN	Polycythemia vera	Blood and bone marrow cancer	General Drugs	MIMS HK
55	MERCAPTOPURINE	Acute lymphoblastic leukaemia	Blood and bone marrow cancer	General Drugs	MIMS HK
56	METHOTREXATE	Acute lymphoblastic leukaemia	Blood and bone marrow cancer	General Drugs	MIMS HK
57	THIOGUANINE	Acute lymphoblastic leukaemia	Blood and bone marrow cancer	General Drugs	MIMS HK
58	THIOGUANINE	Acute myeloid leukaemia	Blood and bone marrow cancer	General Drugs	MIMS HK
59	THIOGUANINE	Chronic myeloid leukaemia	Blood and bone marrow cancer	General Drugs	MIMS HK
60	TRETINOIN	Acute promyelocytic leukaemia	Blood and bone marrow cancer	General Drugs	MIMS HK
61	VINCRIStINE	Acute lymphoblastic leukaemia	Blood and bone marrow cancer	General Drugs	MIMS HK
62	VINCRIStINE	Acute myeloid leukaemia	Blood and bone marrow cancer	General Drugs	MIMS HK
63	ARSENIC TRIOXIDE	Acute promyelocytic leukaemia	Blood and bone marrow cancer	Special Drugs	MIMS HK
64	BLINATUMOMAB	Philadelphia chromosome-negative precursor B-cell Acute lymphoblastic leukaemia	Blood and bone marrow cancer	Special Drugs	MIMS HK
65	BUSULPHAN	Chronic myeloid leukaemia	Blood and bone marrow cancer	Special Drugs	MIMS HK
66	CLADRIBINE	B cell Chronic lymphocytic leukaemia	Blood and bone marrow cancer	Special Drugs	MIMS HK
67	CLADRIBINE	Hairy cell leukaemia	Blood and bone marrow cancer	Special Drugs	MIMS HK
68	CLOFARABINE	Acute lymphoblastic leukaemia	Blood and bone marrow cancer	Special Drugs	MIMS HK
69	CRISANTASPASE (ASPARAGINASE ERW)	Acute lymphoblastic leukaemia	Blood and bone marrow cancer	Special Drugs	MIMS HK
70	DASATINIB	Chronic myeloid leukaemia	Blood and bone marrow cancer	Special Drugs	MIMS HK
71	FLUDARABINE	B cell Chronic lymphocytic leukaemia	Blood and bone marrow cancer	Special Drugs	MIMS HK
72	IMATINIB	Accelerated phase Philadelphia chromosome positive chronic myelogenous leukaemia	Blood and bone marrow cancer	Special Drugs	MIMS HK
73	IMATINIB	Blast phase Philadelphia chromosome positive chronic myelogenous leukaemia	Blood and bone marrow cancer	Special Drugs	MIMS HK
74	IMATINIB	Chronic phase Philadelphia chromosome positive chronic myelogenous leukaemia	Blood and bone marrow cancer	Special Drugs	MIMS HK
75	IMATINIB	Philadelphia chromosome-positive Acute lymphoblastic leukaemia	Blood and bone marrow cancer	Special Drugs	MIMS HK
76	IMATINIB	Myelodysplastic/myeloproliferative disease	Blood and bone marrow cancer	Special Drugs	MIMS HK
77	MITOXANTRONE	Blast crisis in Chronic myeloid leukaemia	Blood and bone marrow cancer	Special Drugs	MIMS HK
78	MITOXANTRONE	Acute myeloid leukaemia	Blood and bone marrow cancer	Special Drugs	MIMS HK
79	PEGASPARAGINASE	Acute lymphoblastic leukaemia	Blood and bone marrow cancer	Special Drugs	MIMS HK
80	ALEMTUZUMAB (LEMTRADA)	B cell Chronic lymphocytic leukaemia	Blood and bone marrow cancer	Special Drugs	MIMS HK
81	RITUXIMAB	Refractory follicular Lymphoma	Blood and bone marrow cancer	Special Drugs	MIMS HK
82	RITUXIMAB	Relapsed follicular Lymphoma	Blood and bone marrow cancer	Special Drugs	MIMS HK
83	RITUXIMAB	Chronic lymphocytic leukaemia	Blood and bone marrow cancer	Special Drugs	MIMS HK
84	BENDAMUSTINE	Chronic lymphocytic leukaemia	Blood and bone marrow cancer	Self-financed item Without Safety Net	MIMS HK
85	DOXORUBICIN (LIPOSOMAL)	Acute leukaemia	Blood and bone marrow cancer	Self-financed item Without Safety Net	MIMS HK
86	OBINUTUZUMAB	Chronic lymphocytic leukaemia	Blood and bone marrow cancer	Self-financed item Without Safety Net	MIMS HK
87	VENETOCLAX	Chronic lymphocytic leukaemia	Blood and bone marrow cancer	Self-financed item Without Safety Net	MIMS HK
88	VENETOCLAX	Small lymphocytic Lymphoma	Blood and bone marrow cancer	Self-financed item Without Safety Net	MIMS HK
89	VENETOCLAX	Acute myeloid leukaemia	Blood and bone marrow cancer	Self-financed item Without Safety Net	MIMS HK

90	LENALIDOMIDE	Myelodysplastic syndrome	Blood and bone marrow cancer	Self-financed item Without Safety Net	MIMS HK
91	RITUXIMAB	Chronic lymphocytic leukaemia	Blood and bone marrow cancer	Self-financed item Without Safety Net	MIMS HK
92	CYCLOPHOSPHAMIDE	Advanced mycosis fungoides	Blood cancer	General Drugs	MIMS HK
93	VINBLASTINE	Advanced mycosis fungoides	Blood cancer	General Drugs	MIMS HK
94	DOXORUBICIN	Osteosarcoma	Bone cancer	General Drugs	MIMS HK
95	DOXORUBICIN (LIPOSOMAL)	Osteosarcoma	Bone cancer	Self-financed item Without Safety Net	MIMS HK
96	IXAZOMIB	In combination with dexamethasone for the treatment of Multiple myeloma in patients who have received at least one prior therapy 與地塞米松組合使用，用於治療曾接受最少一次先前療程的多發性骨髓瘤患者	Bone marrow cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
97	LENALIDOMIDE	Multiple myeloma (MM) 多發性骨髓瘤	Bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund & CCF Medical Assistance Programmes)	HA Website
98	LENALIDOMIDE	In combination with dexamethasone for the treatment of Multiple myeloma in patients who have received at least one prior therapy 與地塞米松組合使用，用於治療曾接受最少一次先前療程的多發性骨髓瘤患者	Bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund & CCF Medical Assistance Programmes)	HA Website
99	BENDAMUSTINE	Multiple myeloma	Bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	MIMS HK
100	BORTEZOMIB	Multiple myeloma	Bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	MIMS HK
101	POMALIDOMIDE	Multiple myeloma (MM) 多發性骨髓瘤	Bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
102	Plerixafor	Multiple myeloma (MM) 多發性骨髓瘤	Bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
103	CARMUSTINE	Multiple myeloma	Bone marrow cancer	General Drugs	MIMS HK
104	CYCLOPHOSPHAMIDE	Multiple myeloma	Bone marrow cancer	General Drugs	MIMS HK
105	EPIRUBICIN	Multiple myeloma	Bone marrow cancer	General Drugs	MIMS HK
106	MELPHALAN	Multiple myeloma	Bone marrow cancer	General Drugs	MIMS HK
107	THALIDOMIDE	Multiple myeloma	Bone marrow cancer	General Drugs	MIMS HK
108	CARFILZOMIB	Multiple myeloma	Bone marrow cancer	Self-financed item With Safety Net (Samaritan Fund)	MIMS HK
109	BENDAMUSTINE	Multiple myeloma	Bone marrow cancer	Self-financed item Without Safety Net	MIMS HK
110	BORTEZOMIB	Multiple myeloma	Bone marrow cancer	Self-financed item Without Safety Net	MIMS HK
111	CARFILZOMIB	Multiple myeloma	Bone marrow cancer	Self-financed item Without Safety Net	MIMS HK
112	DARATUMUMAB	Multiple myeloma	Bone marrow cancer	Self-financed item Without Safety Net	MIMS HK
113	DOXORUBICIN (LIPOSOMAL)	Multiple myeloma	Bone marrow cancer	Self-financed item Without Safety Net	MIMS HK
114	LENALIDOMIDE	Multiple myeloma	Bone marrow cancer	Self-financed item Without Safety Net	MIMS HK
115	ACTINOMYCIN D	Ewing's sarcoma	Bone or soft tissue cancer	General Drugs	MIMS HK
116	CYCLOPHOSPHAMIDE	Ewing's sarcoma	Bone or soft tissue cancer	General Drugs	MIMS HK
117	DACARBAZINE	Soft tissue sarcoma	Bone or soft tissue cancer	General Drugs	MIMS HK
118	DOXORUBICIN	Advanced Soft tissue sarcoma	Bone or soft tissue cancer	General Drugs	MIMS HK
119	MELPHALAN	Soft tissue sarcoma	Bone or soft tissue cancer	General Drugs	MIMS HK
120	DOXORUBICIN (LIPOSOMAL)	Advanced Soft tissue sarcoma	Bone or soft tissue cancer	Self-financed item Without Safety Net	MIMS HK
121	PAZOPANIB	Advanced Soft tissue sarcoma	Bone or soft tissue cancer	Self-financed item Without Safety Net	MIMS HK
122	CARMUSTINE	Malignant glioma	Brain and spinal cord cancer	General Drugs	MIMS HK
123	TEMOZOLOMIDE	Recurrent high grade glioma 復發的惡性神經膠質瘤	Brain cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
124	CARMUSTINE	Recurrent glioblastoma multiforme	Brain cancer	General Drugs	MIMS HK
125	TEMOZOLOMIDE	glioblastoma multiforme	Brain cancer	Special Drugs	MIMS HK
126	TEMOZOLOMIDE	Refractory anaplastic astrocytoma	Brain cancer	Special Drugs	MIMS HK

127	TEMOZOLOMIDE	Anaplastic astrocytoma	Brain cancer	Special Drugs	MIMS HK
128	TEMOZOLOMIDE	Recurrent glioblastoma multiforme	Brain cancer	Special Drugs	MIMS HK
129	BEVACIZUMAB	Glioblastoma	Brain cancer	Self-financed item Without Safety Net	MIMS HK
130	PACLITAXEL	HER2-overexpressing advanced or metastatic breast cancer	Breast cancer	General Drugs	MIMS HK
131	PACLITAXEL (ALBUMIN)	HER2-overexpressing advanced or metastatic breast cancer	Breast cancer	Self-financed item Without Safety Net	MIMS HK
132	BEVACIZUMAB	Cervical cancer	Cervical cancer	Self-financed item Without Safety Net	MIMS HK
133	PEMBROLIZUMAB	PD-L1 expression in metastatic cervical cancer	Cervical cancer	Self-financed item Without Safety Net	MIMS HK
134	PEMBROLIZUMAB	PD-L1 expression in recurrent cervical cancer	Cervical cancer	Self-financed item Without Safety Net	MIMS HK
135	TOPOTECAN	Cervical cancer	Cervical cancer	Self-financed item Without Safety Net	MIMS HK
136	PEMBROLIZUMAB	Metastatic microsatellite instability-high colorectal cancer	Colorectal cancer	Self-financed item Without Safety Net	MIMS HK
137	DAUNORUBICIN	AIDS-related Kaposi's sarcoma	Endothelial cell cancer	General Drugs	MIMS HK
138	PACLITAXEL	AIDS-related Kaposi's sarcoma	Endothelial cell cancer	General Drugs	MIMS HK
139	VINBLASTINE	Kaposi's sarcoma	Endothelial cell cancer	General Drugs	MIMS HK
140	DOXORUBICIN (LIPOSOMAL)	AIDS-related Kaposi's sarcoma	Endothelial cell cancer	Self-financed item Without Safety Net	MIMS HK
141	PACLITAXEL (ALBUMIN)	AIDS-related Kaposi's sarcoma	Endothelial cell cancer	Self-financed item Without Safety Net	MIMS HK
142	PEMBROLIZUMAB	PD-L1 expression in metastatic gastroesophageal junction adenocarcinoma	Esophagus cancer	Self-financed item Without Safety Net	MIMS HK
143	PEMBROLIZUMAB	PD-L1 expression in recurrent locally advanced gastroesophageal junction adenocarcinoma	Esophagus cancer	Self-financed item Without Safety Net	MIMS HK
144	CYCLOPHOSPHAMIDE	Retinoblastoma	Eye cancer	General Drugs	MIMS HK
145	OLAPARIB	As maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade fallopian tube cancer who are in complete or partial response after first-line platinum based chemotherapy ( FIGO III-IV 期 ) 高分化晚期上輸卵管癌患者 · 有 BRCA 1/2 基因突變 ( 生殖細胞及 / 或體細胞突變 ) 而完成一線鉑類化療療程後有完全或部分緩解的維持治療	Fallopian tube cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
146	NIRAPARIB (TOSYLATE)	Fallopian tube cancer	Fallopian tube cancer	Self-financed item Without Safety Net	MIMS HK
147	IMATINIB	Gastrointestinal stromal tumour 胃腸道間質瘤	Gastrointestinal cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
148	EVEROLIMUS (AFINITOR) (OR EQUIV)	Neuroendocrine tumours of gastrointestinal origin	Gastrointestinal cancer	Special Drugs	MIMS HK
149	IMATINIB	Gastrointestinal stromal tumour	Gastrointestinal cancer	Special Drugs	MIMS HK
150	REGORAFENIB	Unresectable, metastatic malignant gastrointestinal stromal tumours	Gastrointestinal cancer	Self-financed item Without Safety Net	MIMS HK
151	BLEOMYCIN	Testicular tumours	Germ cell tumor	General Drugs	MIMS HK
152	CISPLATIN	Metastatic Testicular tumours	Germ cell tumor	General Drugs	MIMS HK
153	ETOPOSIDE	Testicular cancer	Germ cell tumor	General Drugs	MIMS HK
154	VINBLASTINE	Testicular cancer	Germ cell tumor	General Drugs	MIMS HK
155	METHOTREXATE	Trophoblastic neoplasm	Gestational trophoblastic cancer	General Drugs	MIMS HK
156	MITOMYCIN	Head and neck cancer	Head and neck cancer	General Drugs	MIMS HK
157	DOCETAXEL	Head and neck cancer	Head and neck cancer	Special Drugs	MIMS HK
158	DOCETAXEL	Head and neck cancer	Head and neck cancer	Self-financed item Without Safety Net	MIMS HK
159	VINBLASTINE	Langerhans cell histiocytosis	Histiocytes cancer	General Drugs	MIMS HK
160	Axitinib	Advanced renal cell carcinoma (RCC)	Kidney cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
161	ACTINOMYCIN D	Wilm's tumour	Kidney cancer	General Drugs	MIMS HK
162	DOXORUBICIN	Wilm's tumour	Kidney cancer	General Drugs	MIMS HK
163	VINCRISTINE	Wilm's tumour	Kidney cancer	General Drugs	MIMS HK
164	DOXORUBICIN (LIPOSOMAL)	Wilm's tumour	Kidney cancer	Self-financed item Without Safety Net	MIMS HK
165	SUNITINIB	Advanced Renal Cell Carcinoma (RCC)	Kidney cancer	Self-financed item Without Safety Net	MIMS HK
166	LENVATINIB	For first-line treatment of patients with unresectable hepatocellular carcinoma (HCC) 用於無法以手術切除腫瘤的肝癌病人 · 作第一線治療	Liver cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website

167	SORAFENIB	Hepatocellular carcinoma (HCC) 肝細胞癌	Liver cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
168	CABOZANTINIB (CABOMETYX)	Monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults who have previously been	Liver cancer	Self-financed item Without Safety Net	MIMS HK
169	LENVATINIB	Unresectable hepatocellular carcinoma	Liver cancer	Self-financed item Without Safety Net	MIMS HK
170	NIVOLUMAB	Hepatocellular carcinoma	Liver cancer	Self-financed item Without Safety Net	MIMS HK
171	PEMBROLIZUMAB	For first-line treatment for metastatic non-Small cell lung cancer (NSCLC) with high PD-L1 expression (Tumor Proportion Score >=50%) with no EGFR or ALK genomic tumor aberrations 用於 PD-L1 水平高 (腫瘤比例評分 ≥ 50%) · 且沒有表皮生長因子受體(EGFR)或間變性淋巴瘤激酶(ALK)基因突變的轉移性非小細胞肺癌的成年患者 · 作一線治療	Lung cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
172	ALECTINIB	ALK+ve non-Small cell lung cancer (NSCLC) (first-line treatment) 間變性淋巴瘤激酶(ALK)呈陽性非小細胞肺癌 (一線治療)	Lung cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
173	ALECTINIB	ALK+ve metastatic non-Small cell lung cancer] (NSCLC), progressed on Crizotinib and intolerant to Ceritinib, or have CNS-progression after Crizotinib~ ALK 陽性的晚期非小細胞肺癌 · 患者接受克唑替尼治療中惡化而對塞瑞替尼不耐受 · 或曾接受過克唑替尼治療而出現中樞神經系統轉移~	Lung cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
174	CRIZOTINIB	ALK+ve non-Small cell lung cancer (NSCLC) ALK 呈陽性非小細胞肺癌	Lung cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
175	CRIZOTINIB	ROS1-positive non-Small cell lung cancer (NSCLC) ROS1 呈陽性非小細胞肺癌	Lung cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website
176	CERITINIB	ALK+ve non-Small cell lung cancer (NSCLC) ALK 呈陽性非小細胞肺癌	Lung cancer	Self-financed item With Safety Net (Samaritan Fund & CCF Medical Assistance Programmes)	HA Website
177	CERITINIB	For adult patients with ALK+ve advanced non-Small cell lung cancer (NSCLC) previously treated with Crizotinib 曾經接受克唑替尼療程 · ALK 呈陽性晚期非小細胞肺癌的成年患者	Lung cancer	Self-financed item With Safety Net (Samaritan Fund & CCF Medical Assistance Programmes)	HA Website
178	CARBOPLATIN	Small cell lung cancer	Lung cancer	General Drugs	MIMS HK
179	CYCLOPHOSPHAMIDE	Small cell lung cancer	Lung cancer	General Drugs	MIMS HK
180	ETOPOSIDE	Small cell lung cancer	Lung cancer	General Drugs	MIMS HK
181	LOMUSTINE	Lung cancer	Lung cancer	General Drugs	MIMS HK
182	VINCRIStINE	Small cell lung cancer	Lung cancer	General Drugs	MIMS HK
183	EVEROLIMUS (AFINITOR) (OR EQUIV)	Neuroendocrine tumours of lung origin	Lung cancer	Special Drugs	MIMS HK
184	PEMETREXED	Malignant pleural mesothelioma	Lung cancer	Special Drugs	MIMS HK
185	TOPOTECAN	Small cell lung cancer	Lung cancer	Self-financed item Without Safety Net	MIMS HK
186	TOPOTECAN	Small cell lung cancer	Lung cancer	Self-financed item Without Safety Net	MIMS HK
187	LORLATINIB	Metastatic non-small cell lung carcinoma	Lung cancer	Self-financed item Without Safety Net	MIMS HK
188	PEMBROLIZUMAB	As monotherapy for the treatment of adult patients with relapsed or refractory classical Hodgkin Lymphoma (cHL) who have failed autologous stem cell transplant (ASCT) and Brentuximab Vedotin (BV), or who are transplant-ineligible and have failed BV 單一治療用於成人患者 · 治療復發或難治性典型何傑金氏淋巴瘤(cHL) · 而患者已曾接受自身幹細胞移植(ASCT)及維布妥昔單抗(BV)治療但失敗 · 或不合適自身幹細胞移植及曾接受維布妥昔單抗(BV)治療但失	Lymphatic system cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
189	BENDAMUSTINE	Non-Hodgkin's Lymphoma	Lymphatic system cancer	Self-financed item With Safety Net (Samaritan Fund)	MIMS HK
190	CLADRIBINE (MAVENCLAD)	Waldenstrom's macroglobulinaemia	Lymphatic system cancer	Self-financed item With Safety Net (Samaritan Fund)	MIMS HK
191	Plerixafor	Non-Hodgkin's Lymphoma (NHL) 非何傑金氏淋巴瘤	Lymphatic system cancer	Self-financed item With Safety Net (Samaritan Fund)	HA Website

192	OBINUTUZUMAB	Follicular Lymphoma 濾泡性淋巴瘤	Lymphatic system cancer	Self-financed item With Safety Net (Samaritan Fund & CCF Medical Assistance Programmes)	HA Website
193	CARMUSTINE	Hodgkin's disease	Lymphatic system cancer	General Drugs	MIMS HK
194	CARMUSTINE	Non-Hodgkin's Lymphoma	Lymphatic system cancer	General Drugs	MIMS HK
195	CHLORAMBUCIL	Hodgkin's disease	Lymphatic system cancer	General Drugs	MIMS HK
196	CHLORAMBUCIL	Non-Hodgkin's Lymphoma	Lymphatic system cancer	General Drugs	MIMS HK
197	CHLORAMBUCIL	Waldenstrom's macroglobulinaemia	Lymphatic system cancer	General Drugs	MIMS HK
198	CYCLOPHOSPHAMIDE	Hodgkin's Lymphoma	Lymphatic system cancer	General Drugs	MIMS HK
199	CYCLOPHOSPHAMIDE	Non-Hodgkin's Lymphoma	Lymphatic system cancer	General Drugs	MIMS HK
200	DACARBAZINE	Hodgkin's disease	Lymphatic system cancer	General Drugs	MIMS HK
201	DOXORUBICIN	Hodgkin's Lymphoma	Lymphatic system cancer	General Drugs	MIMS HK
202	LOMUSTINE	Hodgkin's Lymphoma	Lymphatic system cancer	General Drugs	MIMS HK
203	METHOTREXATE	Burkitt's Lymphoma	Lymphatic system cancer	General Drugs	MIMS HK
204	PROCARBAZINE	Hodgkin's disease	Lymphatic system cancer	General Drugs	MIMS HK
205	VINBLASTINE	Hodgkin's disease	Lymphatic system cancer	General Drugs	MIMS HK
206	VINBLASTINE	Lymphocytic Lymphoma	Lymphatic system cancer	General Drugs	MIMS HK
207	VINCRISTINE	Hodgkin's disease	Lymphatic system cancer	General Drugs	MIMS HK
208	VINCRISTINE	Non-Hodgkin's Lymphoma	Lymphatic system cancer	General Drugs	MIMS HK
209	CLADRIBINE	Waldenstrom's macroglobulinaemia	Lymphatic system cancer	Special Drugs	MIMS HK
210	MITOXANTRONE	Non-Hodgkin's Lymphoma	Lymphatic system cancer	Special Drugs	MIMS HK
211	RITUXIMAB	CD20-positive diffuse large B cell Non-Hodgkin's Lymphoma	Lymphatic system cancer	Special Drugs	MIMS HK
212	RITUXIMAB	Advanced follicular Non-Hodgkin's Lymphoma	Lymphatic system cancer	Special Drugs	MIMS HK
213	RITUXIMAB	CD20-positive non-progressing low-grade Non-Hodgkin's Lymphoma	Lymphatic system cancer	Special Drugs	MIMS HK
214	ACALABRUTINIB	Mantle cell Lymphoma (MCL) in adult patients who have received at least 1 prior therapy.	Lymphatic system cancer	Self-financed item Without Safety Net	MIMS HK
215	ACALABRUTINIB	Chronic lymphocytic leukaemia (CLL) in adults	Lymphatic system cancer	Self-financed item Without Safety Net	MIMS HK
216	BENDAMUSTINE	Non-Hodgkin's Lymphoma	Lymphatic system cancer	Self-financed item Without Safety Net	MIMS HK
217	BORTEZOMIB	Mantle cell Lymphoma	Lymphatic system cancer	Self-financed item Without Safety Net	MIMS HK
218	BRENTUXIMAB VEDOTIN	Hodgkin's disease	Lymphatic system cancer	Self-financed item Without Safety Net	MIMS HK
219	BRENTUXIMAB VEDOTIN	Anaplastic large cell Lymphoma	Lymphatic system cancer	Self-financed item Without Safety Net	MIMS HK
220	BRENTUXIMAB VEDOTIN	CD-30 positive cutaneous T-cell Lymphoma	Lymphatic system cancer	Self-financed item Without Safety Net	MIMS HK
221	DOXORUBICIN (LIPOSOMAL)	Hodgkin's Lymphoma	Lymphatic system cancer	Self-financed item Without Safety Net	MIMS HK
222	DOXORUBICIN (LIPOSOMAL)	Non-Hodgkin's Lymphoma	Lymphatic system cancer	Self-financed item Without Safety Net	MIMS HK
223	NIVOLUMAB	Refractory classical Hodgkin Lymphoma	Lymphatic system cancer	Self-financed item Without Safety Net	MIMS HK
224	NIVOLUMAB	Relapsed classical Hodgkin Lymphoma	Lymphatic system cancer	Self-financed item Without Safety Net	MIMS HK
225	OBINUTUZUMAB	Follicular Lymphoma	Lymphatic system cancer	Self-financed item Without Safety Net	MIMS HK
226	OBINUTUZUMAB	Refractory follicular Lymphoma	Lymphatic system cancer	Self-financed item Without Safety Net	MIMS HK
227	OBINUTUZUMAB	Relapsed follicular Lymphoma	Lymphatic system cancer	Self-financed item Without Safety Net	MIMS HK
228	PEMBROLIZUMAB	Refractory classical Hodgkin Lymphoma	Lymphatic system cancer	Self-financed item Without Safety Net	MIMS HK
229	PEMBROLIZUMAB	Relapsed classical Hodgkin Lymphoma	Lymphatic system cancer	Self-financed item Without Safety Net	MIMS HK
230	PEMBROLIZUMAB	Primary mediastinal large B-cell Lymphoma	Lymphatic system cancer	Self-financed item Without Safety Net	MIMS HK
231	POLATUZUMAB VEDOTIN	Refractory diffuse large B-cell Lymphoma	Lymphatic system cancer	Self-financed item Without Safety Net	MIMS HK
232	POLATUZUMAB VEDOTIN	Relapsed diffuse large B-cell Lymphoma	Lymphatic system cancer	Self-financed item Without Safety Net	MIMS HK
233	LENALIDOMIDE	Mantle cell Lymphoma	Lymphatic system cancer	Self-financed item Without Safety Net	MIMS HK
234	LENALIDOMIDE	Follicular Lymphoma	Lymphatic system cancer	Self-financed item Without Safety Net	MIMS HK

235	LENALIDOMIDE	Marginal zone Lymphoma	Lymphatic system cancer	Self-financed item Without Safety Net	MIMS HK
236	RITUXIMAB	Refractory follicular Lymphoma	Lymphatic system cancer	Self-financed item Without Safety Net	MIMS HK
237	RITUXIMAB	Relapsed follicular Lymphoma	Lymphatic system cancer	Self-financed item Without Safety Net	MIMS HK
238	RITUXIMAB	CD20-positive diffuse large B cell Non-Hodgkin's Lymphoma	Lymphatic system cancer	Self-financed item Without Safety Net	MIMS HK
239	RITUXIMAB	Advanced follicular Non-Hodgkin's Lymphoma	Lymphatic system cancer	Self-financed item Without Safety Net	MIMS HK
240	RITUXIMAB	CD20-positive non-progressing low-grade Non-Hodgkin's Lymphoma	Lymphatic system cancer	Self-financed item Without Safety Net	MIMS HK
241	OCTREOTIDE	Severe secretory diarrhoea associated with vasoactive intestinal peptide-secreting tumour	Neuroendocrine cancer	General Drugs	MIMS HK
242	OCTREOTIDE	Diarrhoea associated with carcinoid tumour	Neuroendocrine cancer	General Drugs	MIMS HK
243	OCTREOTIDE	Flushing associated with carcinoid tumour	Neuroendocrine cancer	General Drugs	MIMS HK
244	LANREOTIDE	Carcinoid syndrome	Neuroendocrine cancer	Special Drugs	MIMS HK
245	OLAPARIB	As maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian cancer who are in complete or partial response after first-line platinum based chemotherapy. ( FIGO III-IV 期 ) 高分化晚期上皮性卵巢癌患者 · 有 BRCA 1/2 基因突變 ( 生殖細胞及 / 或體細胞突變 ) 而完成一線鉑類化療療程後有完全或部分緩解的維持治療	Ovarian cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
246	FLUOROURACIL	Pancreatic carcinoma	Pancreatic cancer	General Drugs	MIMS HK
247	GEMCITABINE	Pancreatic Cancer	Pancreatic cancer	General Drugs	MIMS HK
248	IRINOTECAN	Metastatic adenocarcinoma of pancreas	Pancreatic cancer	General Drugs	MIMS HK
249	MITOMYCIN	Pancreatic cancer	Pancreatic cancer	General Drugs	MIMS HK
250	PACLITAXEL	Metastatic adenocarcinoma of pancreas	Pancreatic cancer	General Drugs	MIMS HK
251	OCTREOTIDE	Necrolytic migratory erythema associated with glucagonoma	Pancreatic cancer	General Drugs	MIMS HK
252	ERLOTINIB	Metastatic pancreatic cancer	Pancreatic cancer	Special Drugs	MIMS HK
253	EVEROLIMUS (AFINITOR) (OR EQUIV)	Neuroendocrine tumours of pancreatic origin	Pancreatic cancer	Special Drugs	MIMS HK
254	EVEROLIMUS (AFINITOR) (OR EQUIV)	Unresectable or metastatic, well- or moderately-differentiated neuroendocrine tumours of pancreatic	Pancreatic cancer	Self-financed item Without Safety Net	MIMS HK
255	PACLITAXEL (ALBUMIN)	Metastatic adenocarcinoma of pancreas	Pancreatic cancer	Self-financed item Without Safety Net	MIMS HK
256	SUNITINIB	Advanced Pancreatic Neuroendocrine Tumors (pNET)	Pancreatic cancer	Self-financed item Without Safety Net	MIMS HK
257	OLAPARIB	As maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade primary peritoneal cancer who are in complete or partial response after first-line platinum based chemotherapy ( FIGO III-IV 期 ) 高分化晚期上原發性腹膜癌成人患者 · 有 BRCA 1/2 基因突變 ( 生殖細胞及 / 或體細胞突變 ) 而完成一線鉑類化療療程後有完全或部分緩解的維持治療	Peritoneal cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
258	NIRAPARIB (TOSYLATE)	primary peritoneal cancer	Peritoneal cancer	Self-financed item Without Safety Net	MIMS HK
259	BEVACIZUMAB	With carboplatin and paclitaxel for front-line fallopian tube [fallopian tube cancers] / primary peritoneal cancer 與卡鉑和紫杉醇併用於晚期輸卵管癌和原發性腹膜癌的第一線治療	Peritoneum cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
260	ABIRATERONE	For metastatic castration resistant prostate cancer (mCRPC) progressed on or after docetaxel-based chemotherapy regimen 適用於治療藥物或手術去勢抗性的轉移性前列腺癌 · 並且已使用過多西紫杉醇(Docetaxel)而治療無效者	Prostate cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
261	ABIRATERONE	For the treatment of adult men with metastatic castration resistant prostate cancer (mCRPC) who are unsuitable for Docetaxel treatment on the basis of predicted intolerance to Docetaxel 適用於治療成年男性藥物或手術去勢抗性的轉移性前列腺癌 · 而基於預期對多西紫杉醇(Docetaxel) 治療不耐受 · 患者不適合接受多西紫杉醇(Docetaxel)治療	Prostate cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
262	ENZALUTAMIDE	For metastatic castration resistant prostate cancer (mCRPC) progressed on or after docetaxel-based chemotherapy regimen 適用於治療藥物或手術去勢抗性的轉移性前列腺癌 · 並且已使用過多西紫杉醇(Docetaxel)而治療無效者	Prostate cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
263	ENZALUTAMIDE	For the treatment of adult men with metastatic castration resistant prostate cancer (mCRPC) who are unsuitable for Docetaxel treatment on the basis of predicted intolerance to Docetaxel 適用於治療成年男性藥物或手術去勢抗性的轉移性前列腺癌 · 而基於預期對多西紫杉醇(Docetaxel) 治療不耐受 · 患者不適合接受多西紫杉醇(Docetaxel)治療	Prostate cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website

264	DABRAFENIB	For the treatment of adult patients with BRAF V600 mutation-positive unresectable or Metastatic melanoma	Skin cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
265	DABRAFENIB	For the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection 作為術後輔助治療·用於已完全切除腫瘤的 BRAF V600突變 III 期黑色素瘤成人患者	Skin cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
266	NIVOLUMAB	As monotherapy for BRAF V600 wild-type unresectable or Metastatic melanoma 適用於治療 BRAF V600 野生型不可切除或轉移性黑色素瘤之單一藥劑治療	Skin cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
267	NIVOLUMAB	For adjuvant treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection 作為輔助性治療·用於腫瘤已擴散至淋巴結或其他部位·並已完全切除腫瘤的黑色素瘤患者	Skin cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
268	NIVOLUMAB	For the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after platinum based therapy 治療接受含鉑化學治療時或之後疾病惡化的復發或轉移性頭頸部鱗狀細胞癌(SCCHN)病人	Skin cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
269	TRAMETINIB	For the treatment of adult patients with BRAF V600 mutation-positive unresectable or Metastatic melanoma	Skin cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
270	TRAMETINIB	For the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection 作為術後輔助治療·用於已完全切除腫瘤的 BRAF V600突變 III 期黑色素瘤成人患者	Skin cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
271	VEMURAFENIB	As monotherapy for the treatment of adult patients with BRAF V600 mutation-positive unresectable or Metastatic melanoma 用於成年病人以治療 BRAF V600 突變呈陽性而不能切除的或轉移性黑色素瘤的單一療法	Skin cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
272	PEMBROLIZUMAB	Treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy 治療局部晚期或轉移性泌尿道上皮癌·用於在接受鉑類組合化療期間或之後出現病情惡化·或於十二個月內接受過鉑類組合化療作為術前或術後治療的患者	Skin cancer	Self-financed item With Safety Net (CCF Medical Assistance Programmes)	HA Website
273	CETUXIMAB	Locally advanced squamous cell carcinoma of the head and neck	skin cancer	Special Drugs	MIMS HK
274	CETUXIMAB	Metastatic squamous cell carcinoma of the head and neck	skin cancer	Special Drugs	MIMS HK
275	CETUXIMAB	Recurrent squamous cell carcinoma of the head and neck	skin cancer	Special Drugs	MIMS HK
276	DACARBAZINE	Metastatic melanoma	Skin cancer	General Drugs	MIMS HK
277	LOMUSTINE	Metastatic malignant melanoma	Skin cancer	General Drugs	MIMS HK
278	MELPHALAN	Malignant melanoma	Skin cancer	General Drugs	MIMS HK
279	IMATINIB	Dermatofibrosarcoma protuberans	Skin cancer	Special Drugs	MIMS HK
280	CETUXIMAB	Locally advanced squamous cell carcinoma of the head and neck	Skin cancer	Self-financed item Without Safety Net	MIMS HK
281	CETUXIMAB	Metastatic squamous cell carcinoma of the head and neck / Recurrent squamous cell carcinoma of the	Skin cancer	Self-financed item Without Safety Net	MIMS HK
282	NIVOLUMAB	Locally advanced squamous cell carcinoma of the head and neck	Skin cancer	Self-financed item Without Safety Net	MIMS HK
283	NIVOLUMAB	Metastatic squamous cell carcinoma of the head and neck	Skin cancer	Self-financed item Without Safety Net	MIMS HK
284	NIVOLUMAB	Metastatic melanoma	Skin cancer	Self-financed item Without Safety Net	MIMS HK
285	PEMBROLIZUMAB	PD-L1 expression in metastatic squamous cell carcinoma of the head and neck	Skin cancer	Self-financed item Without Safety Net	MIMS HK
286	PEMBROLIZUMAB	PD-L1 expression in unresectable recurrent squamous cell carcinoma of the head and neck	Skin cancer	Self-financed item Without Safety Net	MIMS HK
287	PEMBROLIZUMAB	Metastatic melanoma	Skin cancer	Self-financed item Without Safety Net	MIMS HK
288	PEMBROLIZUMAB	Metastatic squamous cell carcinoma of the head and neck	Skin cancer	Self-financed item Without Safety Net	MIMS HK
289	PEMBROLIZUMAB	Recurrent squamous cell carcinoma of the head and neck	Skin cancer	Self-financed item Without Safety Net	MIMS HK
290	IFOSFAMIDE	Germ cell testicular carcinoma	Testicular cancer	Special Drugs	MIMS HK
291	METHOTREXATE	Choriocarcinoma	Trophoblastic cancer	General Drugs	MIMS HK

**\*There are four categories of drugs in the HA Drug Formulary:**

General Drugs	These are drugs with well-established indications and cost- effectiveness which are available for general use as indicated by patients with relevant clinical conditions and provided at standard fees and charges in public hospitals and clinics.
Special Drugs	These are drugs used under specific clinical conditions with specific specialist authorisation. Special drugs are provided at standard fees and charges in public hospitals and clinics when prescribed under specific clinical conditions. Patients who do not meet the specified clinical conditions but choose to use Special drugs are required to pay for the drugs.
Self-financed Items (SFIs) with Safety Net	These are drugs which are proven to be of significant clinical benefits but are very expensive for HA to provide as part of its standard services. These drugs are not covered by the standard fees and charges in public hospitals and clinics. Patients who require these drugs and can afford the costs have to purchase the drugs at their own expense. A safety net is provided through relevant funds to subsidize the drug expenses of patients who have financial difficulties.
SFIs without Safety Net	These include drugs with preliminary medical evidence only, drugs with marginal benefits over available alternatives but at significant higher costs, and lifestyle drugs (e.g. anti-obesity drugs). These drugs are not provided as part of HA's standard services nor covered by the standard fees and charges in public hospitals and clinics. Patients who choose to use these drugs must purchase them at their own expense.

Source: <https://www.ha.org.hk/hadf/en-us/Drug-Formulary-Management.html>